BioSpace News Archive

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will host an investment community webcast to provide a Company update on Thursday, December 14, 2023.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.

Gyros Protein Technologies AB and Biotage announced a partnership to offer Biotage® PeptiPEC, based on Gyros’ PurePep® EasyClean catch and release technology, on Biotage® Extrahera™ automated sample preparation system.

Cosmos Health Inc. announced an agreement with Cloudpharm PC to acquire the rights arising from the patent filed with the World Intellectual Property Organization, under reference code PCT/EP2023/071865.

Partillion Bioscience Corporation, a life science tools company, announced the commercial availability of two new products that accelerate antibody discovery from mouse antibody-secreting cells.

The global AI in drug discovery market size will hit around USD 15.44 billion by 2032 and growing at a CAGR of 29.66% from 2023 to 2032.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.

The global population health management market size was exhibited at USD 59.61 billion in 2022 and is projected to hit around USD 431.87 billion by 2032, growing at a CAGR of 21.9% during the forecast period 2023 to 2032.

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today announced that the United States Food and Drug Administration (FDA) has approved Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®.

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry